Filing Flows › Health Care › LivaNova (LIVN)
LivaNova (LIVN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · LivaNova (LIVN) Q3 2026 earnings results →
Q3 2026 Revenue up 10% year over year to $393M · 9¢ of every $1 of revenue kept as net profit · operating margin 7.2%
LivaNova made $393M in Q3 2026 (+10% Y/Y). Operating margin 7.2%, net earnings $34.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $393.1M in Q3 2026, up 10% year over year and up 1% from the previous quarter.
Gross margin was 67.4%, down 1.0 points from Q3 2025. Operating profit was $28.4M, a 7.2% margin (down 7.9 points year over year). Operating profit fell $25.6M even though revenue rose $35.4M versus Q3 2025, so costs grew faster than sales. Operating expenses grew 24% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+808%). Net earnings were $34.3M, up 28% year over year. The effective tax rate was 26.5%. Non-operating items added $18.3M, 39% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $73.7M (down 13% year over year), 215% of net earnings. Non-cash charges added back $15.5M of depreciation and amortization and $14.6M of share-based compensation. Working capital and other items added $9.3M. After purchases of property, plant, and equipment, net ($17.9M), adjusted free cash flow as the company reports it was $55.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $393M | +10% | 7.2% | $34.3M | $73.7M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $391M | +11% | 12.7% | $109M | $66.6M |
| Q1 2026 | 10-Q | May 6, 2026 | $362M | +14% | 11.4% | $22.3M | $15.2M |
| Q4 2025 | 10-K | Feb 25, 2026 | $361M | +12% | 11.8% | $30.9M | $82.4M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $358M | +12% | 15.1% | $26.8M | $85.1M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $353M | +11% | 15.4% | $27.2M | $62.9M |
| Q1 2025 | 10-Q | May 7, 2025 | $317M | +7% | 15.3% | −$327M | $24.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About LivaNova
LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova’s mission to “create ingenious medical solutions that ignite patient turnarounds.” LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.” LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation.
In its own words, from its 10-K, filed Feb 25, 2026.
LivaNova against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +14%. Operating margin: 7.2% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
| BLFS Biolife Solutions | Q2 2026 | $28.5M | +22% | 6.0% |
Source: LivaNova 10-Q on SEC EDGAR · CIK 1639691 · Electromedical & Electrotherapeutic Apparatus
More on LIVN
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results